{"nctId":"NCT00145509","briefTitle":"40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)","startDateStruct":{"date":"2005-08"},"conditions":["Bipolar Disorder"],"count":77,"armGroups":[{"label":"Asenapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Asenapine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Asenapine","otherNames":["Org 5222"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have bipolar I disorder (current episode manic or mixed), be treated with lithium or valproic acid, and have completed the a 12-week lead-in trial\n\nExclusion Criteria:\n\n* Have an unstable medical condition or clinically significant laboratory abnormality.\n* Have a primary diagnosis other than bipolar I disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Experienced an Adverse Event","description":"Participants who experienced treatment-emergent adverse events, defined as adverse events reported on or after the first dose of study medication in the 12-week lead-in study through the last dose of study drug + 7 days (or + 30 days for serious adverse events).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Because of an Adverse Event","description":"Participants who discontinued study medication due to adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 52 on the Young-Mania Rating Scale (Y-MRS) Score","description":"The Y-MRS is an 11-item, clinician-rated instrument used for assessing the symptoms of mania. Y-MRS total score range = 0-60; higher scores indicate greater severity of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.2","spread":"13.65"},{"groupId":"OG001","value":"-19.7","spread":"11.81"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 52 on the Montgomery Asberg Depression Rating Scale (MADRS) Score","description":"The MADRS is a 10-item clinician-rated scale for assessing the severity of symptoms of depression. MADRS total score range = 0-60; higher scores indicate greater severity of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"9.75"},{"groupId":"OG001","value":"-3.9","spread":"7.71"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":41},"commonTop":["HEADACHE","INSOMNIA","SOMNOLENCE","SEDATION","ANXIETY"]}}}